2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
J

2020 ASCO Highlights on HER2+ MBC: Is Tucatinib the First TKI to Demonstrate Prolongation of OS in Patients With Brain Mets?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Jane Meisel
By 2020 ASCO Virtual Direct™ Highlights FEATURING Jane Meisel
0 views
July 13, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy
Breast
16:43
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HR+ EBC: Can We De-escalate Adjuvant Chemotherap…

Feat. C. Ma
10:45
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ EBC: Is T-DM1 + Pertuzumab Superior in IDF…

Feat. C. Ma
05:01
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Early TNBC: Does Metronomic Capecitabine Improve…

Feat. C. Ma
11:33
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on ER+ MBC: Fulvestrant vs. Letrozole + Palboci…

Feat. J. Meisel
09:18
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HER2+ MBC: Is Tucatinib the First TKI to Dem…

Feat. J. Meisel
11:47
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Metastatic TNBC: Are Chemoimmunotherapy Pemb…

Feat. J. Meisel
05:09
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on MBC: Is There a Survival Benefit for Surgery?

Feat. J. Meisel
14:57
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ Curative Setting BC: Who Should Be Conside…

Feat. R. L. Mahtani
15:12
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ Curative Setting BC: Pertuzumab to SoC Tra…

Feat. R. L. Mahtani
17:22
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2 Targeted Therapy in HER2+ MBC: Efficacy Com…

Feat. R. L. Mahtani